{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:02:01Z","timestamp":1786978921668,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":91,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972966","type":"print"},{"value":"9783031972973","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97297-3_15","type":"book-chapter","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:08:41Z","timestamp":1761325721000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GMP Manufacturing of Allogenic iPSC-NK Cells for Immunotherapy"],"prefix":"10.1007","author":[{"given":"Hongliang","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"15_CR1","unstructured":"A cell: a case study-based approach to integrating QbD principles in Cell-based Therapy CMC programs."},{"key":"15_CR2","unstructured":"EMA guidelines of 22.11.2017 good manufacturing practice for advanced therapy medicinal products."},{"key":"15_CR3","unstructured":"FDA guidance for industry: chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs)."},{"key":"15_CR4","unstructured":"FDA guidance for industry: current good tissue practice (CGTP) and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products (HCT\/Ps)."},{"key":"15_CR5","unstructured":"IPSE guide: advanced therapy medicinal products (ATMPs) autologous cell therapy."},{"key":"15_CR6","unstructured":"Package Insert \u2013 YESCARTA."},{"key":"15_CR7","unstructured":"Package Insert-KYMRIAH."},{"key":"15_CR8","unstructured":"PDA Technical Report No. 81 Cell-Based Therapy Control Strategy."},{"key":"15_CR9","unstructured":"Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC\/S) Annex 2A Manufacture of advanced therapy medicinal products for human use."},{"key":"15_CR10","unstructured":"WHO good manufacturing practices for biological products, Annex 2."},{"key":"15_CR11","first-page":"323","volume":"165","author":"E Abraham","year":"2018","unstructured":"Abraham E, Ahmadian BB, Holderness K, Levinson Y, Mcafee E. Platforms for manufacturing allogeneic, autologous and iPSC cell therapy products: an industry perspective. Adv Biochem Eng Biotechnol. 2018;165:323\u201350.","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1038\/s41467-018-07570-7","volume":"9","author":"M Ackermann","year":"2018","unstructured":"Ackermann M, Kempf H, Hetzel M, Hesse C, Hashtchin AR, Brinkert K, Schott JW, Haake K, Kuhnel MP, Glage S, Figueiredo C, Jonigk D, Sewald K, Schambach A, Wronski S, Moritz T, Martin U, Zweigerdt R, Munder A, Lachmann N. Bioreactor-based mass production of human iPSC-derived macrophages enables immunotherapies against bacterial airway infections. Nat Commun. 2018;9:5088.","journal-title":"Nat Commun"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/rme.14.93","volume":"10","author":"PW Andrews","year":"2015","unstructured":"Andrews PW, Baker D, Benvinisty N, Miranda B, Bruce K, Brustle O, Choi M, Choi YM, Crook JM, De Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med. 2015;10:1-44.","journal-title":"Regen Med"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2217\/rme-2019-0145","volume":"15","author":"M Awan","year":"2020","unstructured":"Awan M, Buriak I, Fleck R, Fuller B, Goltsev A, Kerby J, Lowdell M, Mericka P, Petrenko A, Petrenko Y, Rogulska O, Stolzing A, Stacey GN. Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity? Regen Med. 2020;15:1463\u201391.","journal-title":"Regen Med"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14653240902807034","volume":"11","author":"M Berg","year":"2009","unstructured":"Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341\u201355.","journal-title":"Cytotherapy"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856\u201368.","journal-title":"Blood"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA. Human natural killer cells. Blood. 2008;112:461\u20139.","journal-title":"Blood"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"1186224","DOI":"10.3389\/fimmu.2023.1186224","volume":"14","author":"C Capelli","year":"2023","unstructured":"Capelli C, Cuofano C, Pavoni C, Frigerio S, Lisini D, Nava S, Quaroni M, Colombo V, Galli F, Bezukladova S, Panina-Bordignon P, Gaipa G, Comoli P, Cossu G, Martino G, Biondi A, Introna M, Golay J. Potency assays and biomarkers for cell-based advanced therapy medicinal products. Front Immunol. 2023;14:1186224.","journal-title":"Front Immunol"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2003-03-0832","volume":"102","author":"K Chadwick","year":"2003","unstructured":"Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A, Bhatia M. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood. 2003;102:906\u201315.","journal-title":"Blood"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nmeth.1593","volume":"8","author":"G Chen","year":"2011","unstructured":"Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng JM, Thomson JA. Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011;8:424\u20139.","journal-title":"Nat Methods"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.stem.2013.12.005","volume":"14","author":"KG Chen","year":"2014","unstructured":"Chen KG, Mallon BS, Mckay RD, Robey PG. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell. 2014;14:13\u201326.","journal-title":"Cell Stem Cell"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook T, Chu J, Kubat A, Adams S, Thomas R, Gilmour K, O\u2019Connor D, Vora A, Qasim W, Base-Edited CARTG. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389:899\u2013910.","journal-title":"N Engl J Med"},{"key":"15_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111423","volume":"40","author":"R Chimienti","year":"2022","unstructured":"Chimienti R, Baccega T, Torchio S, Manenti F, Pellegrini S, Cospito A, Amabile A, Lombardo MT, Monti P, Sordi V, Lombardo A, Malnati M, Piemonti L. Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I(\u2212\/\u2212) iPSCs for beta cell replacement. Cell Rep. 2022;40:111423.","journal-title":"Cell Rep"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","volume":"180","author":"A Crinier","year":"2020","unstructured":"Crinier A, Narni-Mancinelli E, Ugolini S, Vivier E. SnapShot: natural killer cells. Cell. 2020;180:1280\u20131280.e1.","journal-title":"Cell"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcyt.2022.08.001","volume":"25","author":"JL Dashnau","year":"2023","unstructured":"Dashnau JL, Xue Q, Nelson M, Law E, Cao L, Hei D. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies. Cytotherapy. 2023;25:1\u201313.","journal-title":"Cytotherapy"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1038\/ncomms4244","volume":"5","author":"RC Deller","year":"2014","unstructured":"Deller RC, Vatish M, Mitchell DA, Gibson MI. Synthetic polymers enable non-vitreous cellular cryopreservation by reducing ice crystal growth during thawing. Nat Commun. 2014;5:3244.","journal-title":"Nat Commun"},{"key":"15_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7:e30264.","journal-title":"PLoS One"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/cancers13030577","volume":"13","author":"A Fernandez","year":"2021","unstructured":"Fernandez A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodriguez-Antolin C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martinez J, Fernandez L, Perez-Martinez A. Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy. Cancers (Basel). 2021;13:577.","journal-title":"Cancers (Basel)"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cyto.2006.08.006","volume":"35","author":"AR French","year":"2006","unstructured":"French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine. 2006;35:229\u201334.","journal-title":"Cytokine"},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13036-021-00264-7","volume":"15","author":"OF Garcia-Aponte","year":"2021","unstructured":"Garcia-Aponte OF, Herwig C, Kozma B. Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy. J Biol Eng. 2021;15:13.","journal-title":"J Biol Eng"},{"key":"15_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","volume":"13","author":"BH Goldenson","year":"2022","unstructured":"Goldenson BH, Hor P, Kaufman DS. iPSC-derived natural killer cell therapies \u2013 expansion and targeting. Front Immunol. 2022;13:841107.","journal-title":"Front Immunol"},{"key":"15_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.561553","volume":"11","author":"BH Goldenson","year":"2020","unstructured":"Goldenson BH, Zhu H, Wang YM, Heragu N, Bernareggi D, Ruiz-Cisneros A, Bahena A, Ask EH, Hoel HJ, Malmberg KJ, Kaufman DS. Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles. Front Immunol. 2020;11:561553.","journal-title":"Front Immunol"},{"key":"15_CR33","doi-asserted-by":"crossref","unstructured":"Lovell-Badge R, Anthony E, Barker RA, Bubela T, Brivanlou AH, Carpenter M, Charo RA, Clark A, Clayton E, Cong Y, Daley GQ, Fu J, Fujita M, Greenfield A, Goldman SA, Hill L, Hyun I, Isasi R, Kahn J, Kato K, Kim JS, Kimmelman J, Knoblich JA, Mathews D, Montserrat N, Mosher J, Munsie M, Nakauchi H, Naldini L, Naughton G, Niakan K, Ogbogu U, Pedersen R, Rivron N, Rooke H, Rossant J, Round J, Saitou M, Sipp D, Steffann J,Sugarman J, Surani A, Takahashi J, Tang F, Turner L, Zettler PJ, Zhai X. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. Stem Cell Reports. 2021;16:1398\u20131408","DOI":"10.1016\/j.stemcr.2021.05.012"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fmed.2018.00150","volume":"5","author":"RK Iyer","year":"2018","unstructured":"Iyer RK, Bowles PA, Kim H, Dulgar-Tulloch A. Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Front Med (Lausanne). 2018;5:150.","journal-title":"Front Med (Lausanne)"},{"key":"15_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","volume":"13","author":"CDL Johnson","year":"2022","unstructured":"Johnson CDL, Zale NE, Frary ED, Lomakin JA. Feeder-cell-free and serum-free expansion of natural killer cells using cloudz microspheres, G-Rex6M, and human platelet lysate. Front Immunol. 2022;13:803380.","journal-title":"Front Immunol"},{"key":"15_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/cgt.2014.78","volume":"22","author":"AD Kaiser","year":"2015","unstructured":"Kaiser AD, Assenmacher M, Schroder B, Meyer M, Orentas R, Bethke U, Dropulic B. Towards a commercial process for the manufacture of genetically modified T cells for therapy. Cancer Gene Ther. 2015;22:72\u20138.","journal-title":"Cancer Gene Ther"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"10716","DOI":"10.1073\/pnas.191362598","volume":"98","author":"DS Kaufman","year":"2001","unstructured":"Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA. 2001;98:10716\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","volume":"16","author":"S Kiesgen","year":"2021","unstructured":"Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumilli PS. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat Protoc. 2021;16:1331\u201342.","journal-title":"Nat Protoc"},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.stem.2008.09.001","volume":"3","author":"DC Kirouac","year":"2008","unstructured":"Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell. 2008;3:369\u201381.","journal-title":"Cell Stem Cell"},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5966\/sctm.2012-0084","volume":"2","author":"DA Knorr","year":"2013","unstructured":"Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, Lee DA, Kaufman DS. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2:274\u201383.","journal-title":"Stem Cells Transl Med"},{"key":"15_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3389\/fimmu.2019.00879","volume":"10","author":"S Kweon","year":"2019","unstructured":"Kweon S, Phan MT, Chun S, Yu H, Kim J, Kim S, Lee J, Ali AK, Lee SH, Kim SK, Doh J, Cho D. Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21. Front Immunol. 2019;10:879.","journal-title":"Front Immunol"},{"key":"15_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","volume":"14","author":"N Lapteva","year":"2012","unstructured":"Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14:1131\u201343.","journal-title":"Cytotherapy"},{"key":"15_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1615\/CritRevOncog.2014010931","volume":"19","author":"N Lapteva","year":"2014","unstructured":"Lapteva N, Szmania SM, Van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014;19:121\u201332.","journal-title":"Crit Rev Oncog"},{"key":"15_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.626098","volume":"12","author":"E Liu","year":"2021","unstructured":"Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani K. GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells. Front Immunol. 2021;12:626098.","journal-title":"Front Immunol"},{"key":"15_CR45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"15_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4939-8885-3_7","volume":"1884","author":"S Lorenzo-Herrero","year":"2019","unstructured":"Lorenzo-Herrero S, Sordo-Bahamonde C, Gonzalez S, Lopez-Soto A. CD107a degranulation assay to evaluate immune cell antitumor activity. Methods Mol Biol. 2019;1884:119\u201330.","journal-title":"Methods Mol Biol"},{"key":"15_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nbt1177","volume":"24","author":"TE Ludwig","year":"2006","unstructured":"Ludwig TE, Levenstein ME, Jones JM, Berggren WT, Mitchen ER, Frane JL, Crandall LJ, Daigh CA, Conard KR, Piekarczyk MS, Llanas RA, Thomson JA. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol. 2006;24:185\u20137.","journal-title":"Nat Biotechnol"},{"key":"15_CR48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/cancers11060769","volume":"11","author":"KB Lupo","year":"2019","unstructured":"Lupo KB, Matosevic S. Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel). 2019;11:769.","journal-title":"Cancers (Basel)"},{"key":"15_CR49","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jcyt.2021.05.001","volume":"23","author":"KB Lupo","year":"2021","unstructured":"Lupo KB, Moon JI, Chambers AM, Matosevic S. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions. Cytotherapy. 2021;23:939\u201352.","journal-title":"Cytotherapy"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jcyt.2018.02.188","volume":"20","author":"AM Lyness","year":"2018","unstructured":"Lyness AM, Kraft CL, Picken A, Harriman J, Thomas R. Evaluation of a novel cyclic olefin polymer container system for the cryopreservation of adherent and suspension human cell types. Cytotherapy. 2018;20:S67.","journal-title":"Cytotherapy"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.20050128","volume":"202","author":"RB Mailliard","year":"2005","unstructured":"Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 2005;202:941\u201353.","journal-title":"J Exp Med"},{"key":"15_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/sctm.20-0453","volume":"10","author":"F Manstein","year":"2021","unstructured":"Manstein F, Ullmann K, Kropp C, Halloin C, Triebert W, Franke A, Farr CM, Sahabian A, Haase A, Breitkreuz Y, Peitz M, Brustle O, Kalies S, Martin U, Olmer R, Zweigerdt R. High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling. Stem Cells Transl Med. 2021;10:1063\u201380.","journal-title":"Stem Cells Transl Med"},{"key":"15_CR53","first-page":"1","volume":"2454","author":"D Marotta","year":"2022","unstructured":"Marotta D, Rao C, Fossati V. Human induced pluripotent stem cell (iPSC) handling protocols: maintenance, expansion, and cryopreservation. Methods Mol Biol. 2022;2454:1\u201315.","journal-title":"Methods Mol Biol"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","volume":"20","author":"JS Miller","year":"2014","unstructured":"Miller JS, Rooney CM, Curtsinger J, Mcelmurry R, Mccullar V, Verneris MR, Lapteva N, Mckenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014;20:1252\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"15_CR55","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e31","volume":"18","author":"B Min","year":"2018","unstructured":"Min B, Choi H, Her JH, Jung MY, Kim HJ, Jung MY, Lee EK, Cho SY, Hwang YK, Shin EC. Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy. Immune Netw. 2018;18:e31.","journal-title":"Immune Netw"},{"key":"15_CR56","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41570-022-00407-4","volume":"6","author":"KA Murray","year":"2022","unstructured":"Murray KA, Gibson MI. Chemical approaches to cryopreservation. Nat Rev Chem. 2022;6:579\u201393.","journal-title":"Nat Rev Chem"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"15_CR58","volume-title":"StatPearls","author":"E Ozkan","year":"2024","unstructured":"Ozkan E, Lacerda MP. Genetics, cytogenetic testing and conventional karyotype. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"15_CR59","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1182\/blood-2021-151520","volume":"138","author":"K Patel","year":"2021","unstructured":"Patel K, Bachanova V, Goodman AM, Pagel JM, Griffis K, Anderson M, Atwal S, Bickers C, Szabo P, Wong L, Chu Y-W, Elstrom R, Strati P. Phase I study of FT516, an off-the-shelf iPSC-derived NK cell therapy, in combination with rituximab in patients with relapsed\/refractory B-cell lymphoma. Blood. 2021;138:3873.","journal-title":"Blood"},{"key":"15_CR60","doi-asserted-by":"publisher","unstructured":"Piscopo NJ, Mueller KP, Das A, Hematti P, Murphy WL, Palecek SP, Capitini CM, Saha K. Bioengineering solutions for manufacturing challenges in CAR T cells. Biotechnol J. 2018;13. https:\/\/doi.org\/10.1002\/biot.201700095.","DOI":"10.1002\/biot.201700095"},{"key":"15_CR61","volume-title":"Single-use technology in biopharmaceutical manufacture","author":"R P\u00f6rtner","year":"2019","unstructured":"P\u00f6rtner R, Sebald C, Parida SK, Hoffmeister H. Single-use bioreactors for manufacturing of immune cell therapeutics. In: Single-use technology in biopharmaceutical manufacture. Hoboken: Wiley; 2019."},{"key":"15_CR62","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/ijms21072435","volume":"21","author":"D Rehakova","year":"2020","unstructured":"Rehakova D, Souralova T, Koutna I. Clinical-grade human pluripotent stem cells for cell therapy: characterization strategy. Int J Mol Sci. 2020;21:2435.","journal-title":"Int J Mol Sci"},{"key":"15_CR63","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s42003-020-01218-3","volume":"3","author":"L Rohani","year":"2020","unstructured":"Rohani L, Borys BS, Razian G, Naghsh P, Liu S, Johnson AA, Machiraju P, Holland H, Lewis IA, Groves RA, Toms D, Gordon PMK, Li JW, So T, Dang T, Kallos MS, Rancourt DE. Stirred suspension bioreactors maintain naive pluripotency of human pluripotent stem cells. Commun Biol. 2020;3:492.","journal-title":"Commun Biol"},{"key":"15_CR64","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jcyt.2020.12.004","volume":"23","author":"C Rosell-Valle","year":"2021","unstructured":"Rosell-Valle C, Antunez C, Campos F, Gallot N, Garcia-Arranz M, Garcia-Olmo D, Gutierrez R, Hernan R, Herrera C, Jimenez R, Leyva-Fernandez L, Maldonado-Sanchez R, Munoz-Fernandez R, Nogueras S, Ortiz L, Piudo I, Ranchal I, Rodriguez-Acosta A, Segovia C, Fernandez-Munoz B. Evaluation of the effectiveness of a new cryopreservation system based on a two-compartment vial for the cryopreservation of cell therapy products. Cytotherapy. 2021;23:740\u201353.","journal-title":"Cytotherapy"},{"key":"15_CR65","doi-asserted-by":"publisher","first-page":"10293","DOI":"10.1038\/s41598-020-66845-6","volume":"10","author":"K Sekine","year":"2020","unstructured":"Sekine K, Tsuzuki S, Yasui R, Kobayashi T, Ikeda K, Hamada Y, Kanai E, Camp JG, Treutlein B, Ueno Y, Okamoto S, Taniguchi H. Robust detection of undifferentiated iPSC among differentiated cells. Sci Rep. 2020;10:10293.","journal-title":"Sci Rep"},{"key":"15_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1023\/A:1008025016272","volume":"30","author":"V Singh","year":"1999","unstructured":"Singh V. Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology. 1999;30:149\u201358.","journal-title":"Cytotechnology"},{"key":"15_CR67","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","volume":"123","author":"K Skak","year":"2008","unstructured":"Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008;123:575\u201383.","journal-title":"Immunology"},{"key":"15_CR68","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.12533.1","volume":"7","author":"M Stephenson","year":"2018","unstructured":"Stephenson M, Grayson W. Recent advances in bioreactors for cell-based therapies. F1000Res. 2018;7:F1000 Faculty Rev-517.","journal-title":"F1000Res"},{"key":"15_CR69","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","volume":"170","author":"M Strengell","year":"2003","unstructured":"Strengell M, Matikainen S, Siren J, Lehtonen A, Foster D, Julkunen I, Sareneva T. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003;170:5464\u20139.","journal-title":"J Immunol"},{"key":"15_CR70","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/rme-2018-0095","volume":"13","author":"S Sullivan","year":"2018","unstructured":"Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, Bennaceur Griscelli A, Chandra A, Elwood N, Girard M, Kawamata S, Hanatani T, Latsis T, Lin S, Ludwig TE, Malygina T, Mack A, Mountford JC, Noggle S, Pereira LV, Price J, Sheldon M, Srivastava A, Stachelscheid H, Velayudhan SR, Ward NJ, Turner ML, Barry J, Song J. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13:859\u201366.","journal-title":"Regen Med"},{"key":"15_CR71","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861\u201372.","journal-title":"Cell"},{"key":"15_CR72","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.stem.2016.06.017","volume":"19","author":"N Tapia","year":"2016","unstructured":"Tapia N, Scholer HR. Molecular obstacles to clinical translation of iPSCs. Cell Stem Cell. 2016;19:298\u2013309.","journal-title":"Cell Stem Cell"},{"key":"15_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859177","volume":"13","author":"M Tarannum","year":"2022","unstructured":"Tarannum M, Romee R, Shapiro RM. Innovative strategies to improve the clinical application of NK cell-based immunotherapy. Front Immunol. 2022;13:859177.","journal-title":"Front Immunol"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.exphem.2004.06.013","volume":"32","author":"X Tian","year":"2004","unstructured":"Tian X, Morris JK, Linehan JL, Kaufman DS. Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells. Exp Hematol. 2004;32:1000\u20139.","journal-title":"Exp Hematol"},{"key":"15_CR75","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/cas.14374","volume":"111","author":"T Ueda","year":"2020","unstructured":"Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci. 2020;111:1478\u201390.","journal-title":"Cancer Sci"},{"key":"15_CR76","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1242\/jcs.02553","volume":"118","author":"L Vallier","year":"2005","unstructured":"Vallier L, Alexander M, Pedersen RA. Activin\/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci. 2005;118:4495\u2013509.","journal-title":"J Cell Sci"},{"key":"15_CR77","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood-2004-04-1649","volume":"105","author":"MA Vodyanik","year":"2005","unstructured":"Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood. 2005;105:617\u201326.","journal-title":"Blood"},{"key":"15_CR78","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jcyt.2018.11.001","volume":"21","author":"AK Wagner","year":"2019","unstructured":"Wagner AK, Alici E, Lowdell MW. Characterization of human natural killer cells for therapeutic use. Cytotherapy. 2019;21:315\u201326.","journal-title":"Cytotherapy"},{"key":"15_CR79","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fimmu.2017.00676","volume":"8","author":"J Wagner","year":"2017","unstructured":"Wagner J, Pfannenstiel V, Waldmann A, Bergs JWJ, Brill B, Huenecke S, Klingebiel T, Rodel F, Buchholz CJ, Wels WS, Bader P, Ullrich E. A two-phase expansion protocol combining interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against rhabdomyosarcoma. Front Immunol. 2017;8:676.","journal-title":"Front Immunol"},{"key":"15_CR80","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.bbrc.2005.03.058","volume":"330","author":"G Wang","year":"2005","unstructured":"Wang G, Zhang H, Zhao Y, Li J, Cai J, Wang P, Meng S, Feng J, Miao C, Ding M, Li D, Deng H. Noggin and bFGF cooperate to maintain the pluripotency of human embryonic stem cells in the absence of feeder layers. Biochem Biophys Res Commun. 2005;330:934\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"15_CR81","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","volume":"113","author":"PS Woll","year":"2009","unstructured":"Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009;113:6094\u2013101.","journal-title":"Blood"},{"key":"15_CR82","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","volume":"175","author":"PS Woll","year":"2005","unstructured":"Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005;175:5095\u2013103.","journal-title":"J Immunol"},{"key":"15_CR83","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1634\/stemcells.2005-0299","volume":"24","author":"L Xiao","year":"2006","unstructured":"Xiao L, Yuan X, Sharkis SJ. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells. 2006;24:1476\u201386.","journal-title":"Stem Cells"},{"key":"15_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/7651_2015_310","volume":"1502","author":"Y Yan","year":"2016","unstructured":"Yan Y, Song L, Tsai AC, Ma T, Li Y. Generation of neural progenitor spheres from human pluripotent stem cells in a suspension bioreactor. Methods Mol Biol. 2016;1502:119\u201328.","journal-title":"Methods Mol Biol"},{"key":"15_CR85","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Yanez","year":"2019","unstructured":"Yanez L, Sanchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3:e186.","journal-title":"Hemasphere"},{"key":"15_CR86","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40259-021-00494-7","volume":"35","author":"X Yao","year":"2021","unstructured":"Yao X, Matosevic S. Cryopreservation of NK and T cells without DMSO for adoptive cell-based immunotherapy. BioDrugs. 2021;35:529\u201345.","journal-title":"BioDrugs"},{"key":"15_CR87","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","volume":"9","author":"J Zeng","year":"2017","unstructured":"Zeng J, Tang SY, Toh LL, Wang S. Generation of \u201coff-the-shelf\u201d natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Rep. 2017;9:1796\u2013812.","journal-title":"Stem Cell Rep"},{"key":"15_CR88","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1182\/blood.2019000621","volume":"135","author":"H Zhu","year":"2020","unstructured":"Zhu H, Blum RH, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, Bonello GB, Wu J, Tsai PF, Miller JS, Walcheck B, Valamehr B, Kaufman DS. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020;135:399\u2013410.","journal-title":"Blood"},{"key":"15_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108727","volume":"227","author":"W Zuo","year":"2021","unstructured":"Zuo W, Zhao X. Natural killer cells play an important role in virus infection control: antiviral mechanism, subset expansion and clinical application. Clin Immunol. 2021;227:108727.","journal-title":"Clin Immunol"},{"key":"15_CR90","doi-asserted-by":"crossref","unstructured":"Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, et al. First-In-Human Trial of rhIL-15 and Haploidentical Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia. Blood Adv. 2019; 3:1970\u201380","DOI":"10.1182\/bloodadvances.2018028332"},{"key":"15_CR91","doi-asserted-by":"crossref","unstructured":"Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-Induced Memory-Like Natural Killer Cells Exhibit Enhanced Responses Against Myeloid Leukemia. Sci Transl Med. 2016;8:357ra123","DOI":"10.1126\/scitranslmed.aaf2341"}],"container-title":["Advances in Experimental Medicine and Biology","Cell Therapy Manufacturing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97297-3_15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:06:19Z","timestamp":1784207179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97297-3_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972966","9783031972973"],"references-count":91,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97297-3_15","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"25 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}